{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:36:01Z","timestamp":1789011361201,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ejim.2018.02.001","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T09:34:45Z","timestamp":1544088885000},"page":"7-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Management of unfit elderly patients with chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"58","author":[{"given":"Barbara","family":"Eichhorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Goede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2018.02.001_bb0005","series-title":"SEER cancer statistics review, 1975\u20132011","year":"2014"},{"issue":"27","key":"10.1016\/j.ejim.2018.02.001_bb0010","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65\u202fyears of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2018.02.001_bb0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428190701724785","article-title":"Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia","volume":"49","author":"Thurmes","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.ejim.2018.02.001_bb0020","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.14785","article-title":"Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study","volume":"178","author":"Strati","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ejim.2018.02.001_bb0025","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-017-3176-x","article-title":"Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States","volume":"17","author":"Nabhan","year":"2017","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ejim.2018.02.001_bb0030","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/10428194.2015.1091933","article-title":"Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group","volume":"57","author":"Goede","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.ejim.2018.02.001_bb0035","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2014.107326","article-title":"Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model","volume":"99","author":"Baumann","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ejim.2018.02.001_bb0040","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1532-5415.1968.tb02103.x","article-title":"Cumulative illness rating scale","volume":"16","author":"Linn","year":"1968","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.ejim.2018.02.001_bb0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00280-002-0443-5","article-title":"Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study","volume":"50","author":"Martell","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ejim.2018.02.001_bb0050","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2016.150706","article-title":"Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia","volume":"102","author":"Strati","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ejim.2018.02.001_bb0055","first-page":"1","article-title":"Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group","author":"Goede","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejim.2018.02.001_bb0060","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3324\/haematol.2013.096792","article-title":"Interactions between comorbidity and treatment of chronic lymphocytic leukemia: trial results of the German CLL Study Group","volume":"99","author":"Goede","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.ejim.2018.02.001_bb0065","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejim.2018.02.001_bb0070","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jgo.2015.08.003","article-title":"How I treat chronic lymphocytic leukemia in older patients","volume":"6","author":"Heraly","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.ejim.2018.02.001_bb0075","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.02.001_bb0080","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised, open-label, phase III trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejim.2018.02.001_bb0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejim.2018.02.001_bb0090","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/cncr.22662","article-title":"Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia","volume":"109","author":"Shanafelt","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ejim.2018.02.001_bb0095","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.02.001_bb0100","first-page":"1","article-title":"Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia","volume":"28","author":"Dartigeas","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejim.2018.02.001_bb0105","article-title":"A randomised dose de-escalation study of oral fludarabine, \u00b1oral cyclophosphamide and intravenous rituximab as first-line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged \u226565\u202fyears: final analysis of response and toxicity","volume":"124","author":"Mulligan","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ejim.2018.02.001_bb0110","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4670.4670","article-title":"Low-dose FCR is a safe and effective treatment option for elderly\/comorbid patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Updated results of project Q-lite by Czech CLL study group","volume":"124","author":"Smolej","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejim.2018.02.001_bb0115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3324\/haematol.2012.070755","article-title":"Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia","volume":"98","author":"Bouvet","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ejim.2018.02.001_bb0120","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/blood.V126.23.4156.4156","article-title":"Prognostic impact and risk factors of reducing prescribed doses of fludarabine, cyclophosphamide and rituximab (FCR) during frontline treatment of chronic lymphocytic leukemia (CLL)","volume":"126","author":"Kovacs","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2018.02.001_bb0125","first-page":"3758","volume":"34","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.ejim.2018.02.001_bb0130","article-title":"Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukaemia: primary results from the randomised phase IIIb MABLE study","volume":"56","author":"Michallet","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejim.2018.02.001_bb0135","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ajh.24430","article-title":"A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL","volume":"91","author":"Flinn","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejim.2018.02.001_bb0140","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3109\/10428194.2014.933217","article-title":"Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"56","author":"Ujjani","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejim.2018.02.001_bb0145","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood.V126.23.493.493","article-title":"Safety and efficacy of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia: subgroup analysis of the Green study","volume":"126","author":"Stilgenbauer","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ejim.2018.02.001_bb0150","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.02.001_bb0155","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"issue":"9980","key":"10.1016\/j.ejim.2018.02.001_bb0160","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejim.2018.02.001_bb0165","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1007\/s12325-016-0398-2","article-title":"A systematic review and network meta-analysis to evaluate the comparative efficacy of interventions for unfit patients with chronic lymphocytic leukemia","volume":"33","author":"Stadler","year":"2016","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.ejim.2018.02.001_bb0170","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O'Brien","year":"2014","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.ejim.2018.02.001_bb0175","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2018.02.001_bb0180","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejim.2018.02.001_bb0185","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.1002\/ajh.24715","article-title":"Ibrutinib in very elderly patients with relapsed\/refractory chronic lymphocytic leukemia: a real-world experience of 71 patients treated in France: a study from the French Innovative Leukemia Organization (FILO) group","volume":"92","author":"Michallet","year":"2017","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.ejim.2018.02.001_bb0190","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia","volume":"126","author":"O'Brien","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejim.2018.02.001_bb0195","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejim.2018.02.001_bb0200","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejim.2018.02.001_bb0205","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2018.02.001_bb0210","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax plus rituximab in relapsed\/refractory chronic lymphoid leukemia: phase III MURANO study","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejim.2018.02.001_bb0215","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2017-01-761973","article-title":"Venetoclax and obinutuzumab in chronic lymphocytic leukemia","volume":"129","author":"Fischer","year":"2017","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ejim.2018.02.001_bb0220","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejim.2018.02.001_bb0225","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/leu.2017.47","article-title":"Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)","volume":"31","author":"Chanan-Khan","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.ejim.2018.02.001_bb0230","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.2015.124693","article-title":"Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)","volume":"100","author":"Cramer","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ejim.2018.02.001_bb0235","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.clml.2017.07.004","article-title":"Time to second-line treatment and subsequent relative survival in older patients with relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"17","author":"Ammann","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ejim.2018.02.001_bb0240","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multi-center study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejim.2018.02.001_bb0245","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1586\/17474086.2016.1129893","article-title":"A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia","volume":"9","author":"Randhawa","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"10.1016\/j.ejim.2018.02.001_bb0250","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1634\/theoncologist.2017-0055","article-title":"Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents","volume":"22","author":"Cheson","year":"2017","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ejim.2018.02.001_bb0255","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1188\/16.CJON.E41-E48","article-title":"Managing infusion-related reactions for patients with chronic lymphocytic leukemia receiving obinutuzumab","volume":"20","author":"Dawson","year":"2016","journal-title":"Clin J Oncol Nurs"},{"issue":"5","key":"10.1016\/j.ejim.2018.02.001_bb0260","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3816\/CLM.2009.n.071","article-title":"Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis","volume":"9","author":"Morrison","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"19","key":"10.1016\/j.ejim.2018.02.001_bb0265","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejim.2018.02.001_bb0270","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/17474086.2018.1407645","article-title":"A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia","volume":"11","author":"Tadmor","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"10.1016\/j.ejim.2018.02.001_bb0275","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutre","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.ejim.2018.02.001_bb0280","first-page":"2397","article-title":"Supportive care vital in elderly cancer patients: a report from the 2015 annual conference of the International Society of Geriatric Oncology (SIOG), which focused on the role of supportive care in geriatric oncology","volume":"24","author":"Stepney","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejim.2018.02.001_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e2314","article-title":"Geriatricians, surgeons, and oncologists must work together to improve care for older cancer patients","volume":"344","author":"Wise","year":"2012","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ejim.2018.02.001_bb0290","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3109\/10428194.2014.963077","article-title":"Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia","volume":"56","author":"Goede","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.ejim.2018.02.001_bb0295","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"Bottcher","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620518300517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620518300517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:27:49Z","timestamp":1760606869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620518300517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":59,"alternative-id":["S0953620518300517"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2018.02.001","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of unfit elderly patients with chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2018.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}